(Q40764278)

23 September 2017

Estimating the dose-toxicity curve in completed phase I studies (English)

1 reference

23 September 2017

1

Alexia Iasonos

1 reference

23 September 2017

2

Irina Ostrovnaya

1 reference

PMC publication ID

4849410

23 September 2017

language of work or name

English

0 references

publication date

22 February 2011

1 reference

23 September 2017

Statistics in Medicine

1 reference

23 September 2017

30

1 reference

23 September 2017

17

1 reference

23 September 2017

2117-2129

1 reference

Quality assessment of phase I dose-finding cancer trials: proposal of a checklist

23 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Experimental designs for phase I and phase I/II dose-finding studies

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A semiparametric approach to analysing dose-response data

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A generalization of the probit and logit methods for dose response curves

24 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Kernel estimates of dose response

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Small-sample confidence limits for parameters under inequality constraints with application to quantal bioassay.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Comparison of Isotonic Designs for Dose-Finding

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Translation of innovative designs into phase I trials.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Retrospective analysis of sequential dose-finding designs.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Estimating the probability of toxicity at the target dose following an up-and-down design.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Dose finding using the biased coin up-and-down design and isotonic regression.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

Continual reassessment method: a likelihood approach.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A comparison of two phase I trial designs.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4849410

A Limited Memory Algorithm for Bound Constrained Optimization

19 August 2018

1 reference

Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions

21 January 2018

1 reference

Non-parametric optimal design in dose finding studies

21 January 2018

1 reference

The continual reassessment method for dose-finding studies: a tutorial

21 January 2018

1 reference

A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21341302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An evaluation of phase I cancer clinical trial designs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21341302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21341302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/SIM.4206

1 reference

23 September 2017

1 reference

PMC publication ID

4849410

23 September 2017

PubMed publication ID

21341302

1 reference

PMC publication ID

4849410